Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy

IF 5 3区 医学 Q1 HEMATOLOGY Seminars in hematology Pub Date : 2022-10-01 DOI:10.1053/j.seminhematol.2022.11.003
Cesare Mazzaro , Riccardo Bomben , Laura Gragnani , Marcella Visentini , Gabriele Pozzato , Federico Pozzo , Antonella Zucchetto , Valter Gattei
{"title":"Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy","authors":"Cesare Mazzaro ,&nbsp;Riccardo Bomben ,&nbsp;Laura Gragnani ,&nbsp;Marcella Visentini ,&nbsp;Gabriele Pozzato ,&nbsp;Federico Pozzo ,&nbsp;Antonella Zucchetto ,&nbsp;Valter Gattei","doi":"10.1053/j.seminhematol.2022.11.003","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Hepatitis C virus<span> (HCV) is a hepatotropic and lymphotropic virus, responsible for both chronic hepatitis and extra-hepatic manifestations. Multiple epidemiologic, clinical, biological, and molecular studies have suggested that HCV plays a causal role also in the development of several </span></span>lymphoproliferative disorders, either benign, such as </span>mixed cryoglobulinemia<span>, or malignant, such as B-cell non-Hodgkin lymphomas (NHL). Chronic viral antigenic stimulation of B-lymphocytes plays a fundamental basic role from the onset of lymphoma to its final steps. In the past, several studies demonstrated that the association of pegylated interferon plus </span></span>ribavirin<span> was able to eradicate HCV, with subsequent regression of indolent B-cell low-grade NHL. Other studies have demonstrated that direct antiviral agents (DAAs) therapy have some efficacy in HCV-associated NHL, particularly in patients<span> with low-grade NHL or marginal zone-lymphoma, but these results need to be confirmed in larger studies with longer follow-up. The response rate of antiviral therapy seems favorable also in high grade NHL when DAAs therapy is administered in combination with chemotherapy and therefore antiviral therapy should be considered as a first-line approach in HCV-related NHL.</span></span></p></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0037196322000592","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus, responsible for both chronic hepatitis and extra-hepatic manifestations. Multiple epidemiologic, clinical, biological, and molecular studies have suggested that HCV plays a causal role also in the development of several lymphoproliferative disorders, either benign, such as mixed cryoglobulinemia, or malignant, such as B-cell non-Hodgkin lymphomas (NHL). Chronic viral antigenic stimulation of B-lymphocytes plays a fundamental basic role from the onset of lymphoma to its final steps. In the past, several studies demonstrated that the association of pegylated interferon plus ribavirin was able to eradicate HCV, with subsequent regression of indolent B-cell low-grade NHL. Other studies have demonstrated that direct antiviral agents (DAAs) therapy have some efficacy in HCV-associated NHL, particularly in patients with low-grade NHL or marginal zone-lymphoma, but these results need to be confirmed in larger studies with longer follow-up. The response rate of antiviral therapy seems favorable also in high grade NHL when DAAs therapy is administered in combination with chemotherapy and therefore antiviral therapy should be considered as a first-line approach in HCV-related NHL.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
丙型肝炎病毒相关b细胞淋巴瘤:新型直接抗病毒药物治疗的重要性
丙型肝炎病毒(HCV)是一种嗜肝性和淋巴性病毒,可引起慢性肝炎和肝外表现。多项流行病学、临床、生物学和分子研究表明,HCV在几种淋巴增生性疾病的发展中也起着因果作用,无论是良性的,如混合冷球蛋白血症,还是恶性的,如b细胞非霍奇金淋巴瘤(NHL)。慢性病毒抗原刺激b淋巴细胞从淋巴瘤的发病到最后阶段起着基本的作用。在过去,一些研究表明聚乙二醇化干扰素加利巴韦林能够根除HCV,并随后消退惰性b细胞低级别NHL。其他研究表明,直接抗病毒药物(DAAs)治疗hcv相关NHL有一定疗效,特别是对低级别NHL或边缘区淋巴瘤患者,但这些结果需要在更大规模、更长的随访研究中得到证实。当DAAs治疗与化疗联合使用时,抗病毒治疗的反应率似乎也较好,因此抗病毒治疗应被视为hcv相关NHL的一线治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in hematology
Seminars in hematology 医学-血液学
CiteScore
6.20
自引率
2.80%
发文量
30
审稿时长
35 days
期刊介绍: Seminars in Hematology aims to present subjects of current importance in clinical hematology, including related areas of oncology, hematopathology, and blood banking. The journal''s unique issue structure allows for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering a variety of articles that present dynamic and front-line material immediately influencing the field. Seminars in Hematology is devoted to making the important and current work accessible, comprehensible, and valuable to the practicing physician, young investigator, clinical practitioners, and internists/paediatricians with strong interests in blood diseases. Seminars in Hematology publishes original research, reviews, short communications and mini- reviews.
期刊最新文献
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes. Fast and Furious: changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma Tuning CAR T-cell therapies for efficacy and reduced toxicity License for a CAR T: Examining Patient Eligibility The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1